INTRODUCTION:: Pentoxifylline is a xanthine derivative with potential cardiovascular benefits. AIM:: To evaluate the impact of pentoxifylline on blood pressure (BP) and plasma TNF-α, C-reactive protein (CRP) and IL-6 through a systematic review and meta-analysis of randomized controlled trials. METHODS:: The protocol was registered (PROSPERO: CRD42016035988). The search included PUBMED, ProQuest, Scopus and EMBASE until 1 September 2015 to identify trials reporting BP or inflammatory markers during pentoxifylline therapy. Quantitative data synthesis was performed using a random-effects model, with weighted mean difference (WDF) and 95% confidence intervals (CIs) as summary statistics. RESULTS:: Fifteen studies (16 treatment arms) were found to be eligible for inclusion. Meta-analysis did not suggest any effect of pentoxifylline on either SBP or DBP. Pentoxifylline treatment was associated with a significant reduction in plasma concentrations of TNF-α (WDF: −1.03?pg/ml, 95% CI: −1.54, −0.51; P?<?0.001, 11 treatment arms) and CRP (WDF: −1.39?mg/l, 95% CI: −2.68, −0.10; P?=?0.034, five treatment arms). No alteration in plasma IL-6 concentration was observed. The impact of pentoxifylline on plasma TNF-α levels was found to be positively associated with treatment duration (slope: 0.031; 95% CI: 0.004, 0.057; P?=?0.023) but independent of pentoxifylline dose (slope: −0.0003; 95% CI: −0.002, 0.001; P?=?0.687). CONCLUSION:: Pentoxifylline did not alter BP or plasma IL-6 concentration, but significantly reduced circulating TNF-α and CRP concentrations.
ASJC Scopus subject areas
- Internal Medicine
- Cardiology and Cardiovascular Medicine